MGMT and glioblastoma: Although the usefulness of MGMT promoter methylation analysis in glioblastoma patients for predicting the prognosis and response to chemoradiotherapy with temozolomide has been widely reported, there is still no consensus regarding how to measure MGMTpm% and how to define MGMTpm% cutoff values.